drugset / Trial / NCT04102267
Extended Delivery of Bupivacaine Study in Herniorrhaphy
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a phase 4, randomized, open-label study of the efficacy, safety, and pharmacokinetics of bupivacaine administered as liposomal bupivacaine or continuous infusion via elastomeric pump following unilateral open inguinal herniorrhaphy.
Timeline
- Start
- 2018-07-02
- Primary completion
- 2018-09-03
- Completion
- 2018-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupivacaine | Other / unclassified | 266 mg | Other |
| Subject | Bupivacaine | Other / unclassified | 300 mg | Other |
Indications
No indication recorded.